专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US10179936B2 Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy 有权
公开(公告)号：US10179936B2
公开(公告)日：2019-01-15
申请号：US12772136
申请日：2010-04-30
申请人： Steven Shak , Drew Watson , Xitong Li , Lawrence Lee , Kim Clark-Langone
发明人： Steven Shak , Drew Watson , Xitong Li , Lawrence Lee , Kim Clark-Langone
IPC分类号： C12Q1/6886 , G06F19/20 , G01N33/574 , G16H50/30 , G06F19/00
摘要： Algorithm-based molecular assays that involve measurement of expression levels of prognostic and/or predictive genes, or co-expressed genes thereof, from a biological sample obtained from a cancer patient, and analysis of the measured expression levels to provide information concerning the likelihood of recurrence of colorectal cancer and/or the likelihood of a beneficial response to chemotherapy for the patient are provided herein. Methods of analysis of gene expression values of prognostic and/or predictive genes, as well as methods of identifying gene expression-tumor region ratios, tumor-associated stromal surface area, and gene cliques, i.e. genes that co-express with a validated biomarker and thus may be substituted for that biomarker in an assay, are also provided.

22. 发明申请

US20120270228A1 PREDICTORS OF PATIENT RESPONSE TO TREATMENT WITH EGF RECEPTOR INHIBITORS 审中-公开
标题翻译：患者应用EGF受体抑制剂治疗的预防因素
公开(公告)号：US20120270228A1
公开(公告)日：2012-10-25
申请号：US13542323
申请日：2012-07-05
申请人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
发明人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
摘要翻译：本发明提供了有助于确定个体中EGFR表达的EGFR是否是EGFR抑制剂反应性癌症的方法和组合物，以及用于确定具有EGFR表达癌症的患者的可能性将表现出对 EGFR抑制剂治疗。所述方法通常涉及确定与EGFR抑制剂反应性相关的基因产物的归一化表达水平。

23. 发明授权

US08034565B2 Gene expression markers for breast cancer prognosis 有权
标题翻译：乳腺癌预后的基因表达标志物
公开(公告)号：US08034565B2
公开(公告)日：2011-10-11
申请号：US12478632
申请日：2009-06-04
申请人： Melody A. Cobleigh , Steven Shak , Joffre B. Baker , Maureen T. Cronin
发明人： Melody A. Cobleigh , Steven Shak , Joffre B. Baker , Maureen T. Cronin
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
摘要翻译：本发明提供了在乳腺癌的诊断和/或预后中重要的基因组。

24. 发明申请

US20080318230A1 GENE EXPRESSION MARKERS FOR RESPONSE TO EGFR INHIBITOR DRUGS 审中-公开
标题翻译：基因表达标志物对EGFR抑制剂药物的反应
公开(公告)号：US20080318230A1
公开(公告)日：2008-12-25
申请号：US11949535
申请日：2007-12-03
申请人： David AGUS , Joffre B. Baker , Ron B. Natale , Steven Shak
发明人： David AGUS , Joffre B. Baker , Ron B. Natale , Steven Shak
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译：本发明涉及与癌症相关的预后标志物。特别地，本发明涉及基于石蜡包埋的癌症组织固定样品中基因表达的分子表征的预后方法，其允许医师预测患者是否可能对EGFR抑制剂治疗反应良好。

25. 发明授权

US07371379B2 Dosages for treatment with anti-ErbB2 antibodies 有权
标题翻译：用抗ErbB2抗体治疗的剂量
公开(公告)号：US07371379B2
公开(公告)日：2008-05-13
申请号：US10600152
申请日：2003-06-20
申请人： Sharon A. Baughman , Steven Shak
发明人： Sharon A. Baughman , Steven Shak
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , A61K31/337 , A61K38/00 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/32 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
摘要翻译：本发明涉及以ErbB2的过度表达为特征的疾病的治疗。更具体地，本发明涉及用抗ErbB2抗体治疗易患或被诊断患有过度表达ErbB2的癌细胞的人类患者。

26. 发明授权

US07297526B2 Human DNase 失效
标题翻译：人类DNase
公开(公告)号：US07297526B2
公开(公告)日：2007-11-20
申请号：US10839046
申请日：2004-05-04
申请人： Steven Shak
发明人： Steven Shak
IPC分类号： C12N9/16 , C12N15/00 , C12N5/00 , C07H21/24 , C12P21/06
CPC分类号： C12Q1/6876 , A61K38/00 , C12N9/22 , C12N11/08 , C12N15/71 , C12N15/85 , C12N2800/108 , C12N2830/42 , C12N2840/44
摘要： DNA isolates coding for human DNase and methods of obtaining such DNA are provided, together with expression systems for recombinant production of human DNase useful in therapeutic or diagnostic compositions.
摘要翻译：提供了编码人DNase的DNA分离物和获得这样的DNA的方法，以及可用于治疗或诊断组合物的用于重组生产人类DNA的表达系统。

27. 发明申请

US20050260646A1 Gene expression markers for predicting response to chemotherapy 有权
标题翻译：用于预测化疗反应的基因表达标志物
公开(公告)号：US20050260646A1
公开(公告)日：2005-11-24
申请号：US11102228
申请日：2005-04-07
申请人： Joffre Baker , Steven Shak , Luca Gianni
发明人： Joffre Baker , Steven Shak , Luca Gianni
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , Y10S435/96
摘要： The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy.FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
摘要翻译：本发明提供了一组基因，其表达在癌症的预后中是重要的。特别地，本发明提供了可用于预测癌症患者是否可能对化学疗法有有益治疗反应的基因表达信息。 MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; 肝素 AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1，BCL2，ESR1; 或相应的表达产物，所述报告包括所述受试者具有降低的化疗反应可能性的预测。

28. 发明申请

US20050079518A1 Prediction of likelihood of cancer recurrence 有权
标题翻译：预测癌症复发的可能性
公开(公告)号：US20050079518A1
公开(公告)日：2005-04-14
申请号：US10872063
申请日：2004-06-17
申请人： Joffre Baker , John Bryant , Soonmyung Paik , Steven Shak
发明人： Joffre Baker , John Bryant , Soonmyung Paik , Steven Shak
IPC分类号： A61B20060101 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
摘要翻译：本发明提供了基因组，其表达在癌症，特别是乳腺癌的诊断和/或预后中是重要的。

29. 发明授权

US06348343B2 Human DNase I variants 有权
标题翻译：人类DNase I变体
公开(公告)号：US06348343B2
公开(公告)日：2002-02-19
申请号：US09796774
申请日：2001-02-28
申请人： Robert A. Lazarus , Steven Shak , Jana S. Ulmer
发明人： Robert A. Lazarus , Steven Shak , Jana S. Ulmer
IPC分类号： C12N922
CPC分类号： C12N9/22
摘要： The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.
摘要翻译：本发明涉及具有降低的对肌动蛋白的结合亲和力的人类DNA酶I的氨基酸序列变体。本发明提供了编码这种肌动蛋白抗性变体的核酸序列，从而使得能够以足以临床使用的量生产这些变体。本发明还涉及人DNase I的肌动蛋白抗性变体的药物组合物和治疗用途。

30. 发明授权

US09605318B2 Gene expression markers for predicting response to chemotherapy 有权
公开(公告)号：US09605318B2
公开(公告)日：2017-03-28
申请号：US12941877
申请日：2010-11-08
申请人： Joffre B. Baker , Steven Shak , Luca Gianni
发明人： Joffre B. Baker , Steven Shak , Luca Gianni
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , Y10S435/96
摘要： The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式